RUNX1 and acute myeloid leukemia: Ommen et al. documented that kinetics of molecular relapse was markedly different among AML with NPM1 mutations or with rearrangements such as PML-RARA, RUNX1-RUNX1T1 or CBFb-MYH11, and subsequently developed a mathematical model to predict the time elapsing between molecular and hematologic relapse [38].